# A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

> **NCT06976190** · PHASE3 · RECRUITING · sponsor: **Shanghai Miracogen Inc.** · enrollment: 446 (estimated)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** MRG003 + Pucotenlimab
- **DRUG:** Gemcitabine, Docetaxel, or Capecitabine

## Key facts

- **NCT ID:** NCT06976190
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2029-05
- **Final completion:** 2030-12
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06976190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06976190, "A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06976190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*